ZEISS and Mindpeak partner to advance Multiplex Immunofluorescence (mIF) solutions for pathology

The role of AI in pathology isn’t just evolving – it’s accelerating. It’s helping pathologists turn complex data into faster, more consistent answers for patients. At Mindpeak, we’re proud to be part of that change. Today, we’re taking another big step forward through a new collaboration with PathGroup – one of the leading providers of anatomic, clinical, molecular and digital pathology services in the U.S.

This partnership goes beyond collaboration; it marks a powerful step toward bringing AI into everyday diagnostics. By combining Mindpeak’s proprietary image analysis technology with PathGroup’s extensive, pathologist-led network, we’re laying the groundwork for a new era of precision and efficiency in pathology.

Together, we’ll support pathologists integrate AI seamlessly into their workflows – enhancing speed, consistency and equity in diagnostics. The result: faster, more reliable insights for patients and more time for pathologists to focus on what matters most – patient care.

At Mindpeak, we believe the future of pathology is AI-augmented, not AI-replaced. Through partnerships like this, that future is becoming reality – one slide at a time.

‍

‍

Read more here

We’re proud to introduce PhenoScout AI, our next-generation multiplex immunofluorescence (mIF) analysis solution.

By automating phenotype identification, biomarker quantification, and spatial readouts, PhenoScout AI reduces variability and supports large-scale studies. The solution is designed for pharma, diagnostics, and academic research to accelerate translational medicine.

👉 Learn more

‍

We are delighted to announce that Christiaan Neeleman has joined Mindpeak’s Board of Directors.

With more than 20 years of international leadership experience in life sciences, diagnostics, and health technology - including senior roles at Discovery Life Sciences, Definiens, and Philips Healthcare - Christiaan brings deep expertise that will help accelerate our global expansion.

His proven track record in biomarker development, companion diagnostics, and scaling precision diagnostics businesses aligns perfectly with Mindpeak’s mission: enabling faster, more accurate cancer diagnostics through AI-powered pathology.

We are excited to collaborate with Christiaan as we strengthen partnerships, expand into new markets, and further drive the adoption of AI across clinical and research settings.

Read the full press release here

‍

‍